Search for a trial

Safety and protective efficacy of chemoprophylaxis and sporozoite immunization with Plasmodium falciparum NF135 against homologous and heterologous challenge infection in healthy volunteers in the Netherlands

Primary Objective: To determine the safety and tolerability of NF135.C10 sporozoite immunization under chemoprophylaxisSecondary Objectives:• To determine the dose-dependent protective efficacy of NF135.C10 CPS-immunization against homologous…

Identification of pre-erythrocytic target antigens induced by Plasmodium falciparum sporozoite immunization under chemoprophylaxis.

Primary objective: To delineate the antibody repertoire directed against the pre-erythrocytic stages of Plasmodium falciparum induced by CPS-immunization.Secondary objectives: • To assess the functionality of CPS-immunization induced antibodies.• To…

Experimental human malaria infection after immunization with Plasmodium falciparum sporozoites under chloroquine prophylaxis.

Primary objective: To investigate whether CPS immunization confers protection to a blood stage challenge.Secondary objectives: • To study and compare parasitemia after challenge between study groups• To analyze and compare the immune responses…

Re-exposure of previously immunized and challenged human volunteers to a heterologous strain of P. falciparum sporozoites

To determine protective immunity against a heterologous P. falciparum sporozoites re-challenge after previous CPS immunization and challenge.

Re-exposure of EHMI-8 human volunteers to live malaria sporozoites

Objectives: • Primary objective (parasitological): To explore the longevity of immunity against P. falciparum sporozoite challenge that was induced in the EHMI-8 study. • Secondary objective (immunological): To dissect mechanisms of protection and…

Long-term outcomes of pulmonary function in HIV-infected patients with a history of Pneumocystis jirovecii pneumonia

Assessing the prevalence of pulmonary function testing abnormalities in HIV-infected patients with and without a history of PJP.

An open-label, two-part study to determine the absolute bioavailability (BA) of OZ439 using simultaneous intravenous [14C] OZ439 microdose/800 mg oral dosing and to investigate the pharmacokinetics (PK) of OZ439 granules administered as single doses suspended in different volumes and when co-administered with a single dose of Cobicistat, a string CYP3A4 inhibitor, to healthy subjects in fasted state

Part 1:The purpose of Part 1 of the study is to investigate how much of the OZ439 compound is absorbed into, distributed in, and eliminated from the body (this is called pharmacokinetics) when administered orally as compared to an intravenous (iv;…